Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma.,Leukemia

当前位置： X-MOL 学术 › Leukemia › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma.
Leukemia ( IF 11.4 ) Pub Date : 2021-10-11 , DOI: 10.1038/s41375-021-01433-9
Saurabh Zanwar _{1,

2} , Matthew Ho ₂ , Prashant Kapoor _{1,

2} , Angela Dispenzieri _{1,

2} , Martha Q Lacy _{1,

2} , Morie A Gertz _{1,

2} , Francis K Buadi _{1,

2} , Suzanne R Hayman _{1,

2} , David Dingli _{1,

2} , Taxiarchis Kourelis _{1,

2} , Amie Fonder ₁ , Miriam Hobbs ₁ , Yi Hwa ₁ , Wilson Gonsalves _{1,

2} , Rahma Warsame _{1,

2} , Eli Muchtar _{1,

2} , Nelson Leung _{1,

2,

3} , Robert A Kyle _{1,

2} , S Vincent Rajkumar _{1,

2} , Shaji Kumar _{1,

2}

Affiliation

中文翻译：